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ABSTRACT NontypeableHaemophilus influenzae (NTHi) is a Gram-negative, human-restricted pathogen. Although this bacte-
rium typically colonizes the nasopharynx in the absence of clinical symptoms, it is also one of the major pathogens causing otitis
media (OM) in children. Complement represents an important aspect of the host defense against NTHi. In general, NTHi is effi-
ciently killed by complement-mediated killing; however, various resistance mechanisms have also evolved. Wemeasured the
complement resistance of NTHi isolates isolated from the nasopharynx and the middle ear fluids of OM patients. Furthermore,
we determined the molecular mechanism of NTHi complement resistance. Complement resistance was strongly increased in
isolates from the middle ear, which correlated with decreased binding of IgM.We identified a crucial role for the R2866_0112
gene in complement resistance. Deletion of this gene altered the lipooligosaccharide (LOS) composition of the bacterium, which
increased IgM binding and complement-mediated lysis. In a novel mouse model of coinfection with influenza virus, we demon-
strate decreased virulence for the R2866_0112 deletion mutant. These findings identify a mechanism by which NTHi modifies its
LOS structure to prevent recognition by IgM and activation of complement. Importantly, this mechanism plays a crucial role in
the ability of NTHi to cause OM.
IMPORTANCE NontypeableHaemophilus influenzae (NTHi) colonizes the nasopharynx of especially young children without any
obvious symptoms. However, NTHi is also a major pathogen in otitis media (OM), one of the most common childhood infec-
tions. Although this pathogen is often associated with OM, the mechanism by which this bacterium is able to cause OM is largely
unknown. Our study addresses a key biological question that is highly relevant for child health: what is the molecular mecha-
nism that enables NTHi to cause OM?We show that isolates collected from the middle ear fluid exhibit increased complement
resistance and that the lipooligosaccharide (LOS) structure determines IgM binding and complement activation. Modification of
the LOS structure decreased NTHi virulence in a novel NTHi-influenza A virus coinfection OMmouse model. Our findings may
also have important implications for other Gram-negative pathogens harboring LOS, such asNeisseria meningitidis,Moraxella
catarrhalis, and Bordetella pertussis.
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Nontypeable Haemophilus influenzae (NTHi) is a Gram-negative bacterial pathogen that colonizes the upper respira-
tory tract of humans, generally in the absence of clinical symp-
toms.However, NTHi is also able to ascend the Eustachian tube to
the middle ear and cause inflammation, resulting in otitis media
(OM) (1). As such, NTHi accounts for almost 50% of all bacterial
OM infections (2). Although acute OM is typically self-limiting, it
can also lead to important sequelae such as meningitis and per-
manent hearing loss (3). Despite the fact that OM is one of the
most common childhood diseases, the molecular processes un-
derlying themigration ofNTHi from the nasopharynx to themid-
dle ear are poorly understood.
An important part of the innate immune system intended to
clear pathogenic bacteria is the complement system. Activation of
complement leads to a cascade of protein activation and deposi-
tion of complement factor C3b on the surface of bacteria, includ-
ing NTHi (4), which may result in direct killing through the for-
mation of the membrane-attack complex. NTHi strains are
generally considered to be sensitive to complement-mediated ly-
sis; however, studies have also shown that NTHi possesses com-
plement resistance mechanisms, including variation and modifi-
cations in its lipooligosaccharide (LOS) composition (4). The LOS
structure of NTHi consists of three parts: lipid A, an inner core
comprised of a single 3-deoxy-d-manno-octulosonic acid (Kdo)
linked to three heptoses, and an outer core containing a heteropo-
lymer of mainly glucose and galactose moieties. Additional mod-
ifications have also been reported, including sialic acid,
N-acetylgalactosamine, and phosphorylcholine (5, 6). Variations
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in the composition of the LOS structure have previously been
associatedwith decreased binding of antibodies and reduced com-
plement deposition and have been suggested to contribute to the
development of disease (7-11). Recently an important link be-
tween the presence of NTHi-specific IgM antibodies and coloni-
zation of the host was demonstrated (12). Although IgM binding
and complement resistance were shown to play an important role
in the lower respiratory tract during exacerbation of chronic ob-
structive pulmonary disease (COPD) by NTHi (10), it remains
unclear whether similar immune evasion mechanisms are impor-
tant during OM.
In this study, we investigated the contributions of IgM binding
and complement-mediated killing of NTHi during OM.We show
that NTHi strains isolated from the middle ear of children with
OM are more complement resistant than are strains isolated from
the nasopharynx. This decreased susceptibility correlated with de-
creased binding of IgM to the bacterium.
Expression of the R2866_0112 gene is es-
sential for modifying the LOS structure,
which prevents binding of IgM and con-
fers bacterial resistance to complement-
mediated killing, similar to our observa-
tion in clinical isolates. Finally, using a
novel NTHi OM mouse model, we show
that the R2866_0112 gene plays a crucial
role in virulence.
RESULTS
NTHi isolates from MEF display in-
creased complement resistance. NTHi
isolates were obtained from middle ear
fluid (MEF) and nasopharyngeal swab
(NPS) samples collected from children
with OM. Isolates collected from MEF (n
 22) were significantly more resistant to
complement-mediated killing than were
isolates collected from the nasopharynx
(n  24) (Fig. 1A). To rule out potential attenuation by in vitro
culture, we passaged complement-resistant isolates for 5 genera-
tions in the absence of serum. Subsequent analysis of complement
resistance showed no significant changes, suggesting that the phe-
notype of these minimally passaged strains reflects their in vivo
phenotype (data not shown).
To investigate the mechanism by which NTHi was killed by
serum, we measured surface binding of IgM and IgG. We found
that serum-sensitive isolates (10% survival) showed increased
IgM binding compared to complement-resistant isolates (10%
survival) (Fig. 1B). This difference was not observed for the bind-
ing of IgG (Fig. 1B). The amount of IgM binding correlated with
the ability of serum to kill theNTHi isolates (Fig. 1C), implying an
important role for IgM in activating the classical complement
pathway.
FIG 1 Determination of the complement resistance and IgM binding of clinical NTHi isolates. (A)
Survival of MEF (n 22) and NPS (n 24) isolates was determined in 5% normal human serum and
expressed as percent survival compared to that in 5% heat-inactivated human serum for 60 min. (B)
Serum IgG and IgM binding on 25 serum-sensitive and 21 complement-resistant NTHi isolates was
determined by flow cytometry. Statistical significance was determined with an unpaired t test with
Welch’s correction. *, P 0.05; **, P 0.01. (C) Correlation between complement resistance and IgM
binding.
TABLE 1 Top list of genes identified in the serum resistance GAF screen at 30 min
Fold
difference Bayes, P
R2866
gene name R2866 locus tag R2866 annotation
194.5 1.00E16 R2866_0112 Conserved hypothetical protein
83.2 1.00E16 lpsA2 R2866_1629 Lipooligosaccharide glucosyltransferase LpsA
16.0 1.00E16 lic2A R2866_0033 Lipooligosaccharide biosynthesis protein Lic2A
12.3 1.00E16 galE R2866_0222 UDP-glucose 4-epimerase
–10.6 1.11E16 R2866_0369 Conserved hypothetical protein
9.6 3.35E11 bolA R2866_0424 Morphology-related protein BolA
R2866_0425 Lipoprotein, putative
9.4 1.00E16 lgtF R2866_1822 UDP-glucose-lipooligosaccharide beta 1-4 glucosyltransferase
9.2 1.00E16 lgtc R2866_0326 1,4-Alpha-galactosyltransferase (LgtC)
8.5 2.83E06 R2866_1530 Hypothetical protein
6.2 7.52E07 rfbB R2866_1509 dTDP-glucose 4,6-dehydratase
4.9 1.00E16 galU R2866_1581 Glucose-1-phosphate uridylyltransferase
4.3 3.14E09 rfaD R2866_1286 ADP-L-glycero-D-mannoheptose-6-epimerase
4.0 3.04E13 tex R2866_0016 Probable transcription accessory protein Tex
3.9 2.44E15 lpt6 R2866_0303 PE-tn-6–lipooligosaccharide phosphorylethanolamine transferase
3.9 5.78E07 waaQ R2866_0055 ADP-heptose–lipooligosaccharide heptosyltransferase III
3.9 9.28E09 hgpB R2866_1813 Hemoglobin and hemoglobin-haptoglobin binding protein B
3.9 1.60E07 licA R2866_1070 Phosphorylcholine kinase LicA
3.8 1.00E16 ICE_orf31 R2866_0596 Conserved hypothetical protein p31
3.6 1.78E15 R2866_1296 Conserved hypothetical protein
3.6 1.11E16 accA R2866_0167 Acetyl coenzyme A carboxylase, subunit alpha
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The R2866_0112 gene affects NTHi complement resistance.
In order to identify genes affecting IgM binding and complement
resistance, the negative genome-wide screen genomic array foot-
printing (GAF) was performed (13, 14). For this screen, the se-
quenced complement-resistant strain R2866 was used (15). In to-
tal, 57 transposon mutants showed an attenuated phenotype (see
Table S2 in the supplemental material), of which the top 20 most
attenuated mutants are listed in Table 1. Functional class enrich-
ment analysis showed that the majority of the identified genes
were involved in LOS biosynthesis (Table 2). The R2866_0112
gene, coding for a conserved hypothetical protein, showed the
most prominent phenotype, and transcriptional analysis indi-
cated that expression of this gene was increased in complement-
resistant isolates (Fig. 2A).
To validate a role for R2866_0112 gene expression in comple-
ment resistance, we determined survival of the R2866 wild type,
the R28660112 mutant, and the R2866lgtC strain as a control
because the lgtC gene has previously been shown to confer com-
plement resistance (8). Furthermore, we included the R2866licA
mutant because it showed a minor phenotype in the GAF screen
(see Table S2 in the supplemental material). The 0112 mutant
was extremely sensitive to complement-mediated killing com-
pared to the wild-type, licA mutant, or lgtC mutant strain
(Fig. 2B). Heat inactivation of serum abrogated killing of the
0112 mutant, which showed that the bactericidal activity was
dependent on the action of the complement pathway (Fig. 2B). A
polar effect of the R2866_0112 gene deletion was excluded by
microarray data analysis of the R2866 wild type and the 0112
mutant (Table 3). Besides the expression of R2866_0112 (251-fold
decrease), a minor decrease in expression was observed for the
hemoglobin and hemoglobin-haptoglobin binding protein B gene
(hgpB), as was an increase in expression of gene locus
R2866_1095—R2866_1101. However, the altered expression of
hgpB and gene locus R2866_1095—R2866_1101 was not involved
in complement resistance because deletion did not alter the
complement-sensitive phenotype of the 0112 mutant (Fig. 2C).
To confirm the importance of this gene for complement resistance
in other NTHi strains, we also deleted the R2866_0112-
homologous gene from NTHi Rd, 3655, 86-028NP, and 1521062.
All mutant strains showed strongly reduced complement resis-
tance compared to their respective parental strain, albeit comple-
ment resistance levels varied extensively (Fig. 2D to G).
R2866_0112 gene expression alters the LOS structure.As our
results (Table 2), as well as previous reports, suggested an impor-
tant role for LOS in complement resistance, we determined
whether deletion of the R2866_0112 gene affected the LOS com-
position. As a control, the lgtC mutant was included because
previous reports showed an altered LOS structure for this mutant
in the R2866 strain (8, 16). The 0112mutant showed a different
LOS migration pattern than did the R2866 wild type and lgtC
mutant (Fig. 3A), suggesting that the R2866_0112 gene affects
LOS biosynthesis. Deletion of the R2866_0112-homologous gene
from NTHi Rd, 3655, 86-028NP, and 1521062 also altered the
LOSmigration pattern (see Fig. S1 in the supplemental material),
which confirms a conserved function for this gene.
Although changes in LOS structuremay directly affect comple-
ment resistance by changing membrane stability, this was not the
case for the 0112 mutant because the mutant and wild-type
strains showed similar sensitivities to EDTA (Fig. 3B), which in-
terrupts intermolecular associations between LOS phosphate
groups (10). Also, sensitivity to polymyxin B, which increases
membrane permeability, was equal for the R2866 wild-type and
0112 mutant strains (Fig. 3C). Liquid chromatography-
electrospray ionization-mass spectrometry (LC-ESI-MS) analysis
of the LOS showed that both the R2866 wild-type and 0112mu-
tant strains contained a conserved inner-core triheptosyl moiety
and belong to a group of NTHi strains expressing a heptose
(HepIV) in the outer core (5). The R2866 wild-type LOS showed
major ions at m/z 2124 and 1876, whereas the spectrum of the
0112 mutant showed smaller major ions at m/z 1521 and 1265
(Table 4). In conclusion, the LOS structure of the 0112 mutant
strain showed various truncations, a findingwhich corresponds to
the altered migration pattern (Fig. 3A).
Complement activation is dependent on direct binding of
IgM to NTHi LOS. Because our primary observation in clinical
isolates showed a correlation between IgM binding and comple-
ment resistance, we also determined IgG and IgM binding to the
TABLE 2 Database for annotation, visualization, and integrated
discovery (DAVID) analysis
Functional annotation P value Fold enrichment
Lipopolysaccharide biosynthesis 2.40E05 27.4
Cell outer membrane 7.09E04 11.9
Glycosyltransferase 1.00E05 10.1
Signal 9.74E05 5.9
Cell membrane 1.96E04 2.8
Membrane 0.001 2.5
Transferase 0.007 2.2
TABLE 3 R2866 and R28660112 mutant gene expression array resultsa
R2866 locus tag R2866 annotation
R2866 wild-type
array signal
R28660112
array signal Bayes, P
Fold
difference
R2866_0112 Conserved hypothetical protein 5,345 21 1.00E16 251.3
R2866_1813 Hemoglobin and hemoglobin-haptoglobin binding protein B 5,312 1,249 1.00E16 4.3
R2866_1095 Putative TPRb protein 302 4,685 1.00E16 15.3
R2866_1096 Hypothetical protein 302 6,706 1.00E16 21.9
R2866_1097 Putative TPR protein 604 10,290 1.00E16 16.7
R2866_1098 Hypothetical protein 308 6,610 1.00E16 21.3
R2866_1099 Putative TPR protein 200 9,008 1.00E16 44.4
R2866_1100 Hypothetical protein 309 6,792 1.00E16 21.7
R2866_1101 Putative TPR protein 297 9,918 1.00E16 32.7
a Genes regulated 2.5-fold with P values of0.001 are included in the table.
b TPR, tetratricopeptide repeat.
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R2866 wild type and the 0112 mutant. No significant change in
IgG binding was observed. However, the 0112mutant showed a
~2-fold increase in IgM binding (Fig. 4A). Binding of IgM to the
bacterial surface was essential for killing the 0112 mutant, as
depletion of IgM from serum completely prevented killing
(Fig. 4B). The reduced killing of the 0112 mutant with IgM-
depleted serum was not due to decreased bactericidal activity, be-
cause an NTHi strain dependent on C-reactive protein (CRP)-
mediated complement activation was killed equally as well with
normal serum as with IgM-depleted serum (data not shown). Sera
with different levels of IgM showed a strong correlation between
IgMbinding and killing of the bacteria, confirming the essentiality
of IgM in complement-mediated killing of the 0112 mutant
(Fig. 4C).
To determine whether IgM directly recognizes the LOS of
NTHi,Western blot experimentswere performed.While IgMpre-
dominately binds to the lower bandof thewild-type LOS, IgMalso
binds strongly to the truncated LOS band of the 0112 mutant
(Fig. 4D). The0112mutant LOS bound ~2-fold-more IgM than
did the R2866 wild-type LOS (Fig. 4E), which corresponds to the
flow cytometry results (Fig. 4A). Also, the lgtC mutant showed
an increase in IgM binding, although not significant (Fig. 4E).
FIG 2 The R2866_0112 gene deletion mutant exhibits decreased complement resistance. (A) Relative expression of R2866_112 mRNA was analyzed by
qRT-PCR in 25 serum-sensitive and 21 complement-resistant clinical isolates Statistical significance was determined with an unpaired t test with Welch’s
correction. (B) Complement resistance of R2866, 0112 mutant, and lgtC mutant (n  4) was determined with 40% NHS or 40% heat-inactivated NHS.
Statistical significance was determined with a two-way analysis of variance and the Bonferroni post hoc test. (C) Complement resistance of R2866,0112mutant,
1813 mutant, 1095-1101 mutant, 0112/1813 mutant, and 0112/1095-1101 mutant was determined in 40% NHS (n  4). Statistical significance was
determined with a one-way analysis of variance and the Tukey post hoc test. (D to G) Complement resistance of Rd (HI0461) (D), 86-028NP (NTHI0592) (E),
3655 (CGSHi3655_02894) (F), and 1521062 (G) was determined with 10% (Rd), 20% (3655), or 40% (86-028NP and 1521062) serum, respectively (n  3).
Statistical significance was determined on log10-transformed data with a one-way analysis of variance and the Tukey post hoc test. *, P 0.05; **, P 0.01; ***,
P 0.001; NS, not significant.
TABLE 4 Positive-ion ESI-MS data and proposed compositions for glycoforms in dephosphorylated and permethylated oligosaccharide derived
from NTHi strains R2866 and R28660112a
[MNa]
Relative abundance (%)
Proposed compositionR2866 R28660112
2,736 Trb Hex7 · Hep4 · AnKdo-ol
2,369 9 HexNAc · Hex4 · Hep4 · AnKdo-ol
2,166 8 HexNAc · Hex3 · Hep4 · AnKdo-ol
2,124 19 Hex4 · Hep4 · AnKdo-ol
2,080 10 9 Hex5 · Hep3 · AnKdo-ol
1,920 13 5 Hex3 · Hep4 · AnKdo-ol
1,876 21 7 Hex4 · Hep3 · AnKdo-ol
1,716 9 Hex2 · Hep4 · AnKdo-ol
1,672 6 6 Hex3 · Hep3 · AnKdo-ol
1,521 8 27 Hex1 · Hep4 · AnKdo-ol
1,468 5 Hex2 · Hep3 · AnKdo-ol
1,265 5 35 Hex1 · Hep3 · AnKdo-ol
a The major ions are depicted in bold. All glycoforms contain Hep3 · AnKdo-ol. Points of elongation appear from HexI and/or HepIII in the following structure:
b Tr, traces.
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Furthermore, we determined IgM binding to 4 complement-
resistant and 4 complement-sensitive isolates. In accordance with
the data for the complement-sensitive 0112 mutant, LOS from
complement-sensitive isolates bound significantlymore IgM than
did LOS from complement-resistant isolates (Fig. 4F and G).
Deletion of the R2866_0112 gene attenuates colonization
and otitis media. Although the 0112 mutant was significantly
less resistant to complement-mediated lysis, the consequences
with regard to host colonization and/or OM remain uncertain.
BecauseNTHi by itself does not infectmice efficiently, we adapted
our previously described murine model of influenzae A virus
(IAV)-Streptococcus pneumoniae coinfection (17). In these exper-
iments, mice are primed first with influenza virus or mock treated
and subsequently challenged with NTHi. For these experiments,
we used NTHi strain 1521062, which we had previously used in
animal experiments. Infection of mice with IAV significantly in-
creased the number of NTHi bacteria in the nose at both 48 h and
96 h postchallenge (Fig. 5A). Importantly, IAV infection also fa-
cilitated replication of NTHi in the middle ears (Fig. 5B).
Similar to R2866, deletion of the R2866_0112 gene from the
NTHi 1521062 strain (designated the 1521062 mutant) attenu-
ated complement resistance (see Fig. S2 in the supplemental ma-
terial). IAV-NTHi coinfection experiments with a 1:1 mixture of
the wild type and the mutant strain showed that the mutant was
strongly outcompeted by the wild type. The mutant strain was
attenuated in the nasopharynx as well as the middle ears, both at
48 h and at 96 h (Fig. 5C to H), suggesting that clearance of the
mutant strain already occurs early during infection. Interestingly,
although the CFU counts of the wild type in the nose decreased
slightly from 48 h to 96 h, the CFU counts in the middle ears
increased, suggesting that there is local bacterial replication in the
middle ear cavity. In summary, these data demonstrate an impor-
tant in vivo role for the R2866_0112 gene in complement resis-
tance and bacterial pathogenesis.
DISCUSSION
Although NTHi is generally sensitive to complement-mediated
killing, some strains have developed immune evasionmechanisms
that aid in colonization and disease. Previous data from animal
models suggest that the complement system comprises an impor-
tant aspect of the host defense against NTHi. For instance, deple-
tion of complement by cobra venom resulted in the development
of otitis media in chinchillas by “avirulent” NTHi strains (18).
Recently, it was shown that NTHi isolates from the lower respira-
tory tract exhibit increased complement resistance compared to
colonizing strains (10). Here, we provide strong evidence that
NTHi strains isolated from the middle ears of children suffering
from otitis media are more resistant to complement-mediated
killing than are nasopharyngeal isolates.
The observation that bacterial isolates from themiddle ear cav-
ity show increased complement resistance may be explained by at
least two mechanisms. One explanation is that the local inflam-
matory environment determines the bacterial phenotype of OM
strains. Evidence to support this mechanism is the observation
that serial passage of a serum-sensitive NTHi strain in the pres-
ence of active complement increased its complement resistance
(10). This is particularly relevant in the context of OM, since large
quantities of complement factors are present in the middle ears
during inflammation of the middle ear (19, 20). An alternative
hypothesis is that only complement-resistant NTHi isolates are
able to cause OM, which implies the existence of “colonizing” and
“otitis media” genotypes. Despite a very high level of genetic het-
erogeneity among NTHi strains, especially for LOS synthesis-
related genes (5), clinical isolates causing inflammatory diseases,
including OM, display a distinct genetic profile that confers in-
creased complement resistance (21). Future experiments that in-
vestigate whether these OM isolates are equally efficient at colo-
nizing the mucosal surfaces of the nasopharynx, and whether this
changes in the presence of inflammation (e.g., due to a viral infec-
tion), may shed more light into when and how NTHi requires
complement resistance. Various modifications in the NTHi LOS
structure have previously been described to contribute to comple-
ment resistance. Modification of LOS by the phase-variable LOS
synthesis gene lgtC has been shown to delay C4b deposition on the
bacterium, resulting in increased complement resistance (8). An-
other strategy used by NTHi is the incorporation of sialic acid in
LOS, which also confers protection against complement attack (9)
and leads to prolonged survival in the middle ear cavity in a chin-
chilla model (22). In this study, we identified a complement eva-
sion mechanism, which is dependent on the R2866_0112 gene.
This gene was also identified in a complement resistance screen by
Nakamura et al. (10), and transposon mutants of Rd showed de-
creased growth or survival in the mouse lungs (23). The
FIG 3 The R2866_0112 gene deletion mutant expresses an altered LOS structure. (A) LOS analysis of R2866, 0112 mutant, and lgtC mutant strains by
Tris-Tricine SDS-PAGE and silver staining. (B and C) Outer membrane stability of R2866 wild type and mutant as determined by sensitivity to EDTA (n 5)
(B) or polymyxin B (n 8) (C). Statistical significancewas determinedwith a one-way analysis of variance and the Tukey post hoc test or awith a two-way analysis
of variance and the Bonferroni post hoc test, respectively. OD620, optical density at 620 nm; NS, not significant.
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R2866_0112 gene is highly conserved in all NTHi strains se-
quenced to date, and deletion of the homologous genes from all
NTHi strains that we tested resulted in a dramatic decrease in
complement resistance. Here, we demonstrate a role for the
R2866_0112 gene in LOS structure synthesis. The high number of
truncated glycoforms in LOS of mutant strains lacking this gene,
together with the absence of one dominant LOS glycoform, sug-
gests that the R2866_0112 gene is not a transferase involved in
LOS synthesis directly. Identifying the specific function of this
gene remains the subject of ongoing investigation.
Interestingly, the R2866_0112 genemutant showed an increase
in IgM binding, which was essential for complement-mediated
killing. This was also observed for the clinical isolates, in which
IgM binding correlated with complement resistance. Another
study focusing on COPD also reported decreased binding of IgM
to complement-resistantNTHi isolates from the lower respiratory
tract (10), and recently, Micol et al. showed that patients with
hyper-IgM syndromewere protected fromNTHi colonization but
not from other respiratory pathogens (12). Our results and these
studies both point to an essential function for IgM in the recogni-
tion of NTHi. Consequently, increasing the level of bactericidal
IgM antibodies, either by therapeutic administration or by vacci-
nation, may effectively reduce NTHi colonization as well as dis-
ease. Such a strategy may be highly effective, as an initial study
using a detoxified NTHi LOS protein conjugate vaccine already
showed protection in a chinchilla and mouse model of OM (24,
25).
To assess the importance of the R2866_0112 gene for in vivo
virulence, we made use of a novel murine IAV-NTHi coinfection
model. Here, we show that coinfection of mice with IAV and
NTHi results in enhanced bacterial colonization and progression
to OM, similar to S. pneumoniae (17, 26, 27). A competition ex-
periment between a wild-type strain and a mutant strain lacking
the R2866_0112 gene resulted in a strong attenuation of the mu-
tant in both colonization and survival in the middle ears at 48 h
and 96 h. The exact mechanism by which mice clear NTHi is
currently unclear. Because we used naive mice, polyspecific natu-
ral IgM antibodies may play an important role in this bactericidal
FIG 4 IgM binds R28660112 mutant LOS directly. (A) Serum IgG and IgM binding on R2866 and 0112 mutant as determined by flow cytometry (n 9).
Statistical significance was determined with an unpaired t test with Welch’s correction. (B) Complement resistance of R2866 and 0112 mutant strains was
determined in heat-inactivatedNHS (HI-NHS),NHS, or IgM-depleted serum (n 4). Statistical significancewas determinedwith a one-way analysis of variance
and the Tukey post hoc test. (C) Correlation between 0112mutant serum survival and IgM binding. (D and F) Direct binding of IgM to LOS was analyzed by
silver staining (loading control) and Western blotting. (E) Relative IgM binding to LOS of R2866, 0112, and lgtCmutant was calculated (n 3). (G) Signal
intensities in arbitrary units (AU) of IgM binding to LOS of clinical isolates were calculated (n  4). Statistical significance was determined with a one-way
analysis of variance and the Tukey post hoc test or with an unpaired t test. *, P 0.05; **, P 0.01; NS, not significant.
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effect. A similar effect of natural IgM was observed by Zola et al.
(28), who found a role for these antibodies in limiting NTHi col-
onization in mice. Interestingly, in our study, the mutant was
attenuated not only in the middle ears but also in the nasophar-
ynx, implying similar clearance mechanisms in the middle ears
and the nasopharynx. One possibility is that the primary infection
with IAV allows for abundant complement components to be
present at the mucosal surface of the nasopharynx, thereby pro-
viding selective pressure. Although the exactmechanism bywhich
IAV allows NTHi to replicate in either the nasopharynx or the
middle ear cavity remains currently unclear, these data point to an
important in vivo role for the R2866_0112 gene in complement
resistance and the development of OM.
MATERIALS AND METHODS
Clinical isolates. Children up to 5 years of age who suffered from recur-
rent acute OM (rAOM) or chronic OM with effusion (COME) were en-
rolled in a retrospective clinical cohort study, which was approved by the
Committee on Research Involving Human Subjects of the Radboud Uni-
versity NijmegenMedical Centre (CMO2007/239, international trial reg-
istration number NCT00847756). Legal guardians provided written in-
formed consent. Middle ear fluid was collected during surgery using a
middle ear fluid aspiration system (Kuijpers Instruments, Groesbeek,
FIG 5 The R2866_0112 gene mutant shows decreased virulence in a murine coinfection otitis media model. Mice were inoculated with 104.5 PFU of influenza
A virus (IAV) or mock treated 3 days before intranasal infection with 5 107 CFU of NTHi. (A and B) CFU counts in the nose (A) or the middle ears (B) were
determined 48 and 96 h postinfection (n 10). (C, D, F, and G) Mice were infected with 104.5 PFU of IAV 3 days before intranasal infection with a 1:1 ratio of
NTHi 1521062wild type (WT) and the R2866_0112mutant (5 107 CFU total). CFU counts in the nose (C andD) or themiddle ears (F andG)were determined
48 and 96 h postinfection (n 10). Statistical significance was determinedwith aMann-Whitney test. (E andH)CI scores were calculated. Statistical significance
was determined with a one-way analysis of variance and the Tukey post hoc test. **, P 0.01; ***, P 0.001.
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Netherlands), and nasopharyngeal samples were obtained using a cotton
wool swab (Copan, Brescia, Italy). Middle ear fluid was mixed with 2 ml
saline prior to bacterial culture and stored at 80°C. Isolates were sero-
typed using slide agglutination (BD Biosciences). All clinical isolates were
minimally passaged in vitro (4 passages).
Bacterial strains. Strains used in this study are listed in Table S1 in the
supplemental material. Strains were grown with shaking at 225 rpm in
brain heart infusion (BHI; BD Biosciences) supplemented with 10 g/ml
hemin (Sigma) and 2 g/ml -NAD (Merck), at 37°C and 5% CO2. Live
bacterial counts were determined by plating serial dilutions in phosphate-
buffered saline (PBS) on BHI plates. For mutant libraries and gene dele-
tion mutants, 150 g/ml spectinomycin (Calbiochem) was added.
Generation of H. influenzae R2866 transposon mutant library.
GenomicDNAwas isolatedwithGenomic-tip 20/G (Qiagen) as described
previously (29). The H. influenzae marinerT7 transposon mutant library
was generated as described previously for S. pneumoniae (13) with plas-
mid pGSF8 as a donor of themarinerT7 transposon conferring spectino-
mycin resistance. Mutagenized genomic DNA was introduced into the
bacterium with the M-IV transformation method (30).
Identifying genes involved in complement resistance. Genes in-
volved in resistance to complement-mediated killing were identified by
GAF (13, 14). A volume of 0.1 ml (1 108 CFU/ml), containing approx-
imately 30,000 uniquemutants of the R2866 strain, was added to 0.4ml of
50% normal human serum (NHS; GTI Diagnostics) or heat-inactivated
(20min, 56°C) NHS in phosphate-buffered saline (PBS) containing 0.1%
gelatin (PBSG). Volumes of 100 l were taken at 0, 30, and 60 min of
incubation at 37°C; diluted directly in 5 ml of supplemented BHI (sBHI);
and cultured for 4.5 h. The GAF experiment was performed on two inde-
pendent days in duplicate.
GAF readout was performed essentially as described previously, with
some minor modifications (13). Chromosomal DNA was digested with
HpyCH4V (New England Biolabs). Two micrograms of Cy3-labeled
cDNAwas hybridized to custom-madeH. influenzaeR2866GAFNimble-
gen microarrays. Probe signals were normalized using Analysis of
NimbleGen Arrays Interface Suite (ANAIS) (31). Probes with 2.0-fold
probe signal differences and a Bayesian P value of 0.001 (http://cybert
.microarray.ics.uci.edu) were set as underrepresented following the chal-
lenge.
Generation of NTHi directed gene mutants. Targeted gene deletion
mutants of NTHi were generated by allelic exchange of the target gene
with an antibiotic resistance marker, as described previously for S. pneu-
moniae (14). DNA was introduced into the bacterium with the M-IV
transformation method (30). All primers (Biolegio, Nijmegen, Nether-
lands) used in this study are listed in Table S1 in the supplemental mate-
rial.
qRT-PCR.RNAwas extracted frommid-log-phase-grownNTHi clin-
ical isolates by using the RNeasy minikit (Qiagen) and was DNase treated
(Ambion). One microgram of cDNA was synthesized using the Super-
Script III reverse transcriptase kit (Invitrogen). Quantitative reverse
transcription-PCR (qRT-PCR) was performed in a 20-l reaction mix-
ture with SYBR green PCR Master Mix (Applied Biosystems) on a 7500
Fast Real-Time PCR system (Applied Biosystems). The gyrA, rpoA, and
frdB genes were used as the internal standard genes for GeNorm normal-
ization (32).
R2866 expression microarray analysis. RNA was extracted from
mid-log-phase-grown NTHi R2866 wild-type or R28660112 mutant
cells by using the RNeasy minikit (Qiagen) and was DNase treated (Am-
bion). Cy3-labeled cDNAwas obtained according to the Nimblegen array
user’s guide (http://www.nimblegen.com/products/lit/NG_Expression
_Guide_v5p1.pdf). Two micrograms of Cy3-labeled cDNA was hybrid-
ized to custom-made H. influenzae R2866 expression Nimblegen mi-
croarrays. Probe signals were normalized using Analysis of NimbleGen
Arrays Interface Suite (ANAIS) (31). Genes with a 2.5-fold signal dif-
ference and a Bayesian P value of0.001 (http://cybert.microarray.ics.uci
.edu) were selected to be significantly regulated.
Flow cytometric analysis.Hanks’ buffered salt solution (HBSS) with-
out Ca2/Mg2, containing 5% (vol/vol) heat-inactivated fetal calf se-
rum, was used for all dilutions and washes. Surface opsonization with
serum was performed by incubating bacteria in 5% heat-inactivated
pooled human serum for 1 h at 37°C with 5% CO2. Bacteria were fixed in
2% paraformaldehyde, and surface-bound IgM or IgGwas detected using
anti-human IgG- or IgM-fluorescein isothiocyanate (FITC)-conjugated
antibodies (Sigma) by flow cytometry using a FACSCalibur cytometer
(BD Biosciences). Data were analyzed using FlowJo version 7.6.3.
Serum IgMdepletion. Fivemilliliters of 20%NHSwas incubatedwith
500 l of PBS-washed Sepharose beads coupled to anti-human IgM anti-
body (Sigma). After 2 h of incubation on a rotating wheel at 4°C, Sephar-
ose beads were removed by centrifugation, and sera were diluted to 10%
with PBS and immediately stored at80°C.
Complement resistance assays.All experiments were conducted with
the same batch of pooled human serum obtained from GTI Diagnostics
(catalogue no. PHS-N100). Complement resistance of the NPS and MEF
isolates was determined with 5% NHS or heat-inactivated NHS as de-
scribed previously (10). The complement resistance of NTHi R2866,
3655, 86-028NP, Rd, 1521062, lgtC mutant, and 0112 mutant strains
was determined as described previously (15). To determine the contribu-
tion of IgM, complement resistance was determined in 5% IgM-depleted
serum. For competition experiments, wild-type andmutant bacteria were
mixed in a 1:1 ratio, and serum was added as described above. The com-
petitive index (CI) score was calculated by dividing the output ratio of the
CFUcounts of themutant to those of thewild type by the input ratio of the
mutant to the wild-type bacteria.
LOS analysis by Tris-Tricine SDS-PAGE. LOS was prepared by the
proteinase K-ethanol precipitation method as described previously (33).
LOS samples were separated on a Tris-Tricine SDS-PAGE gel in a Protean
II XI cell electrophoresis system (Bio-Rad) and visualized by silver stain-
ing (34) or transferred to nitrocellulose forWestern blotting. Membranes
were blocked with 5% bovine serum albumin (BSA) in PBS, incubated for
2 h with 2% NHS in PBS, and subsequently incubated with goat anti-
human IgM coupled to horseradish peroxidase (HRP) in PBS (1:5,000).
The intensity of IgM binding to LOS bands was calculated using ImageJ
software (35).
Structural characterization of LOS glycoforms by mass spectrome-
try. LOS was extracted from lyophilized bacteria using phenol-
chloroform-light petroleum as described previously (36). LOS prepara-
tions and LC-ESI-MS experiments were performed as described
previously (37, 38) on a Waters 2690 high-pressure liquid chromatogra-
phy (HPLC) system (Waters, Milford, MA) coupled to a Finnigan LCQ
ion trap mass spectrometer (Finnigan-MAT, San Jose, CA). A microbore
C18 column [Phenomenex Luna; 5-m C18(2) column; 150 by 0.5 mm;
Torrance, CA] was used with an eluent gradient consisting of 0.1 mM
sodium acetate and 1% acetic acid in methanol as eluent A and 0.1 mM
sodium acetate and 1% acetic acid in H2O. Gradient elution was con-
ducted as follows: 50% A at 0 min, 54% A at 15 min, 100% A at 35 min,
54% A at 55 min, and 50% A at 65 to 75 min. The flow rate was 0.018 ml/
min. Average mass units were used for calculation of molecular weight
values providing the basis for proposed compositions: hexose (Hex),
162.14; N-acetyl-hexosamine (HexNAc), 203.19; heptose (Hep), 192.17;
reduced anhydro-Kdo (AnKdo-ol), 222.20;Me, 14.03; Na, 22.99. Relative
abundance was estimated from the height of the ion peaks relative to the
total (expressed as percent).
Influenza virus-NTHi coinfection mouse model. Six- to 8-week-old
female, specific-pathogen-free (SPF) BALB/c mice (Harlan, Netherlands)
were infected intranasally (i.n.) with 104.5 PFU of egg-grown influenza
virus strain A/Udorn/302/72 in a volume of 10 l or a similar dilution of
naive allantoic fluid (17). Three days later, mice were challenged with 5
107 CFU in 10l PBS of either the wild-type 1521062 strain alone or a 1:1
mixture of 1521062 wild-type and mutant strains. At 48 and 96 h follow-
ing challenge with NTHi, mice were euthanized and perfused with PBS by
intracardiac injection. The entire bulla from each ear was dissected, after
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which a nasopharyngeal lavage was performed. Bullae were immediately
homogenized (T10 basic Ultra-turrax; IKA), and serial dilutions of bulla
homogenates and nasopharyngeal lavages were prepared in PBS and cul-
tured on sBHI agar with or without 150g/ml of spectinomycin (Calbio-
chem) (39). The CI score was calculated as described above. All animal
experiments were approved by the Animal Ethics Committee of the Rad-
boud University Nijmegen Medical Centre (RU-DEC2-11-246).
Statistical analysis. All statistical analyses were performed in Graph-
Pad Prism version 4.0 forWindows (GraphPad Software, SanDiego, CA),
where P 0.05 was considered significant.
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